Alnylam Pharmaceuticals (ALNY) is up 5.6% today. Here is some analysis on what might have caused this price movement.
Analysis: The most likely driver is a rebound after last week’s steep selloff following second-quarter results, as investors refocus on how strong the underlying revenue growth was despite lower full-year TTR guidance. This could also be because the recent reset in expectations made the shares look more attractive relative to Alnylam’s still-expanding ATTR franchise and a more favorable competitive setup.
Details:
Second-quarter 2026 global net product revenue reached $1.172 billion, up 74% from a year earlier, while total TTR revenue rose 89% to $1.03 billion.AMVUTTRA revenue topped $1.0 billion in the quarter, showing continued demand growth even as the company trimmed its 2026 TTR revenue outlook.Management lowered full-year 2026 TTR revenue guidance to $4.2 billion to $4.5 billion from $4.4 billion to $4.7 billion, citing slower second-line growth after pent-up launch demand was satisfied.A late-stage ATTR-CM setback for a rival program in July may still be supporting sentiment around Alnylam’s competitive position, especially after the stock had already been heavily punished for its own guidance cut.Sources:
Alnylam, SEC, Fierce Pharma
Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.
$ALNY Insider Trading Activity
$ALNY insiders have traded $ALNY stock on the open market 136 times in the past 6 months. Of those trades, 0 have been purchases and 136 have been sales.
Here’s a breakdown of recent trading of $ALNY stock by insiders over the last 6 months:
- YVONNE GREENSTREET (Chief Executive Officer) has made 0 purchases and 19 sales selling 16,690 shares for an estimated $5,332,821.
- PUSHKAL GARG (EVP Chief R&D) has made 0 purchases and 32 sales selling 15,074 shares for an estimated $4,883,227.
- KEVIN JOSEPH FITZGERALD (CSO & EVP, Head of Research) has made 0 purchases and 28 sales selling 8,541 shares for an estimated $2,754,438.
- JEFFREY V. POULTON (EVP, Chief Financial Officer) has made 0 purchases and 19 sales selling 6,916 shares for an estimated $2,215,352.
- TOLGA TANGULER (EVP, Chief Commercial Officer) has made 0 purchases and 19 sales selling 5,866 shares for an estimated $1,877,015.
- MELISSA MCLAUGHLIN (Chief Human Resources Officer) has made 0 purchases and 14 sales selling 3,910 shares for an estimated $1,274,342.
- DAVID E I PYOTT has made 0 purchases and 5 sales selling 3,830 shares for an estimated $1,145,852.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Quiver Alerts
Receive ALNY Data Alerts
Get market-moving data, filings, and signals for ALNY in real time.
Sign Up
$ALNY Hedge Fund Activity
We have seen 355 institutional investors add shares of $ALNY stock to their portfolio, and 420 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL WORLD INVESTORS removed 5,499,424 shares (-33.7%) from their portfolio in Q1 2026, for an estimated $1,819,594,418
- CAPITAL RESEARCH GLOBAL INVESTORS added 2,691,473 shares (+39.7%) to their portfolio in Q1 2026, for an estimated $890,527,671
- TWO SIGMA INVESTMENTS, LP added 1,376,457 shares (+223.4%) to their portfolio in Q1 2026, for an estimated $455,428,327
- FMR LLC removed 1,322,983 shares (-8.3%) from their portfolio in Q1 2026, for an estimated $437,735,385
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP removed 1,127,162 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $372,944,090
- CLEARBRIDGE INVESTMENTS, LLC added 759,023 shares (+127.1%) to their portfolio in Q1 2026, for an estimated $251,137,940
- MANUFACTURERS LIFE INSURANCE COMPANY, THE added 598,953 shares (+944.5%) to their portfolio in Q1 2026, for an estimated $198,175,579
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$ALNY Analyst Ratings
Wall Street analysts have issued reports on $ALNY in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 06/29/2026
To track analyst ratings and price targets for $ALNY, check out Quiver Quantitative's $ALNY forecast page.
$ALNY Price Targets
Multiple analysts have issued price targets for $ALNY recently. We have seen 10 analysts offer price targets for $ALNY in the last 6 months, with a median target of $427.0.
Here are some recent targets:
- Patrick R. Trucchio from HC Wainwright & Co. set a target price of $470.0 on 06/29/2026
- Eric Joseph from Citigroup set a target price of $380.0 on 05/19/2026
- Derek Archila from Wells Fargo set a target price of $377.0 on 05/01/2026
- Luca Issi from RBC Capital set a target price of $445.0 on 05/01/2026
- Danielle Brill from Truist Securities set a target price of $505.0 on 04/13/2026
- Keay Nakae from Chardan Capital set a target price of $425.0 on 03/25/2026
- Faisal Khurshid from Jefferies set a target price of $330.0 on 03/16/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Read full article here »
View the Zacks #1 Rank List
Alnylam Rises as Investors Reassess Sharp Post-Earnings Pullback
Alnylam Pharmaceuticals (ALNY) is up 5.6% today. Here is some analysis on what might have caused this price movement.
Analysis: The most likely driver is a rebound after last week’s steep selloff following second-quarter results, as investors refocus on how strong the underlying revenue growth was despite lower full-year TTR guidance. This could also be because the recent reset in expectations made the shares look more attractive relative to Alnylam’s still-expanding ATTR franchise and a more favorable competitive setup.
Details:
Sources:
Alnylam, SEC, Fierce Pharma
Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.
$ALNY Insider Trading Activity
$ALNY insiders have traded $ALNY stock on the open market 136 times in the past 6 months. Of those trades, 0 have been purchases and 136 have been sales.
Here’s a breakdown of recent trading of $ALNY stock by insiders over the last 6 months:
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$ALNY Hedge Fund Activity
We have seen 355 institutional investors add shares of $ALNY stock to their portfolio, and 420 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$ALNY Analyst Ratings
Wall Street analysts have issued reports on $ALNY in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
To track analyst ratings and price targets for $ALNY, check out Quiver Quantitative's $ALNY forecast page.
$ALNY Price Targets
Multiple analysts have issued price targets for $ALNY recently. We have seen 10 analysts offer price targets for $ALNY in the last 6 months, with a median target of $427.0.
Here are some recent targets:
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Read full article here »